Qiagen (NYSE:QGEN) Upgraded at UBS Group

UBS Group upgraded shares of Qiagen (NYSE:QGEN) to a hold rating in a report issued on Wednesday morning,Zacks reports.

A number of other equities analysts have also commented on QGEN. Barclays set a $40.00 price objective on Qiagen and gave the stock an “equal weight” rating in a research note on Friday, August 7th. TD Cowen reaffirmed a “hold” rating on shares of Qiagen in a report on Wednesday, July 15th. Stifel Nicolaus set a $40.00 target price on Qiagen in a report on Friday, August 7th. Citigroup reaffirmed a “neutral” rating and issued a $45.00 price target (up from $38.00) on shares of Qiagen in a research report on Monday, August 10th. Finally, JPMorgan Chase & Co. upped their price target on Qiagen from $45.00 to $50.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat, Qiagen presently has an average rating of “Hold” and a consensus target price of $43.51.

Qiagen Price Performance

NYSE QGEN opened at $42.39 on Wednesday. The company has a current ratio of 2.85, a quick ratio of 2.31 and a debt-to-equity ratio of 0.48. The company has a fifty day simple moving average of $42.20 and a 200 day simple moving average of $40.18. The company has a market cap of $8.74 billion, a P/E ratio of 21.72, a P/E/G ratio of 4.20 and a beta of 0.63. Qiagen has a 1 year low of $32.53 and a 1 year high of $57.81.

Qiagen (NYSE:QGEN) last announced its earnings results on Wednesday, August 5th. The company reported $0.62 EPS for the quarter, topping the consensus estimate of $0.60 by $0.02. The firm had revenue of $535.04 million for the quarter, compared to the consensus estimate of $527.50 million. Qiagen had a net margin of 19.49% and a return on equity of 14.47%. The business’s quarterly revenue was up .2% on a year-over-year basis. During the same quarter last year, the firm posted $0.60 EPS. Qiagen has set its FY 2026 guidance at 2.430- EPS. On average, sell-side analysts predict that Qiagen will post 2.43 EPS for the current year.

Institutional Investors Weigh In On Qiagen

Several hedge funds have recently made changes to their positions in QGEN. Baader Bank Aktiengesellschaft acquired a new position in Qiagen in the 1st quarter valued at approximately $1,368,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Qiagen during the 1st quarter worth approximately $2,518,000. Janus Henderson Group PLC bought a new stake in shares of Qiagen during the first quarter valued at approximately $14,647,000. Handelsbanken Fonder AB bought a new stake in shares of Qiagen during the second quarter valued at approximately $2,909,000. Finally, Hsbc Holdings PLC acquired a new position in shares of Qiagen in the first quarter valued at $12,916,000. Institutional investors own 70.00% of the company’s stock.

About Qiagen

QIAGEN N.V. is a global provider of sample preparation, molecular testing and bioinformatics solutions used in life sciences research, molecular diagnostics and applied testing. The company develops technologies that help customers isolate and analyze DNA, RNA and other biological materials from blood, tissue and other samples.

Its offerings include laboratory instruments, consumables, assay kits and software. Key product areas include automated sample-processing systems, polymerase chain reaction (PCR) and digital PCR solutions, next-generation sequencing workflows, bioinformatics tools, and diagnostic tests such as QuantiFERON for tuberculosis testing and QIAstat-Dx for syndromic testing.